These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3825502)

  • 1. Clinical and muscle biopsy findings in malignant hyperthermia susceptibility.
    Ranklev E; Henriksson KG; Fletcher R; Germundsson K; Oldfors A; Kalimo H
    Acta Neurol Scand; 1986 Dec; 74(6):452-9. PubMed ID: 3825502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies.
    Mezin P; Payen JF; Bosson JL; Brambilla E; Stieglitz P
    Br J Anaesth; 1997 Sep; 79(3):327-31. PubMed ID: 9389850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histomorphologic examination of skeletal muscle preparations does not differentiate between malignant hyperthermia-susceptible and -normal patients.
    von Breunig F; Wappler F; Hagel C; von Richthofen V; Fiege M; Weisshorn R; Stavrou D; Schulte am Esch J
    Anesthesiology; 2004 Apr; 100(4):789-94. PubMed ID: 15087612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
    Fiege M; Wappler F; Scholz J; von Richthofen V; Brinken B; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Sep; 33(9):557-63. PubMed ID: 9787864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients.
    Fiege M; Wappler F; Scholz J; Weisshorn R; von Richthofen V; Schulte am Esch J
    J Clin Anesth; 2000 Mar; 12(2):123-8. PubMed ID: 10818326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of malignant hyperthermia in Denmark and Sweden.
    Ording H; Ranklev E; Fletcher R
    Br J Anaesth; 1984 Nov; 56(11):1183-90. PubMed ID: 6487440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia.
    Ording H; Hedengran AM; Skovgaard LT
    Acta Anaesthesiol Scand; 1991 Nov; 35(8):711-6. PubMed ID: 1763590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients.
    Wappler F; Roewer N; Köchling A; Scholz J; Löscher W; Steinfath M
    Anesthesiology; 1996 Jun; 84(6):1280-7. PubMed ID: 8669667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W; Breucking E
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study.
    Schuster F; Metterlein T; Negele S; Kranke P; Muellenbach RM; Schwemmer U; Roewer N; Anetseder M
    Anesth Analg; 2008 Sep; 107(3):909-14. PubMed ID: 18713904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Are morphologic changes in skeletal muscles of patients with malignant hyperthermia diagnostically useful?].
    Anetseder M; Pohl F; Klein R; Müller R; Hoyer A; Horbaschek H; Roggendorf W; Hartung E; Roewer N
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Oct; 34(10):626-33. PubMed ID: 10548959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles.
    Wappler F; Roewer N; Köchling A; Scholz J; Steinfath M; Schulte am Esch J
    Anesth Analg; 1996 Jun; 82(6):1230-6. PubMed ID: 8638796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine.
    Fiege M; Wappler F; Weisshorn R; Gerbershagen MU; Kolodzie K; Schulte Am Esch J
    Anesthesiology; 2003 Apr; 98(4):944-9. PubMed ID: 12657857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia.
    Wappler F; Scholz J; Köchling A; Steinfath M; Krause T; Schulte am Esch J
    Br J Anaesth; 1997 May; 78(5):541-7. PubMed ID: 9175969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological findings in 165 patients explored for malignant hyperthermia susceptibility.
    Figarella-Branger D; Kozak-Ribbens G; Rodet L; Aubert M; Borsarelli J; Cozzone PJ; Pellissier JF
    Neuromuscul Disord; 1993; 3(5-6):553-6. PubMed ID: 8186710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of serotonin-induced contractures in skeletal muscle from malignant hyperthermia-susceptible patients with dantrolene.
    Wappler F; Scholz J; von Richthofen V; Fiege M; Köchling A; Lambrecht W; Schulte am Esch J
    Acta Anaesthesiol Scand; 1997 Nov; 41(10):1312-8. PubMed ID: 9422298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fiber-type caffeine sensitivities in skinned muscle fibers from humans susceptible to malignant hyperthermia.
    Adnet PJ; Bromberg NL; Haudecoeur G; Krivosic I; Adamantidis MM; Reyford H; Bello N; Krivosic Horber RM
    Anesthesiology; 1993 Jan; 78(1):168-77. PubMed ID: 8424551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.